Polyion-sensitive membrane-based electrodes for heparin-binding foldamer analysis

Polymer membrane-based electrodes sensitive to low molecular weight heparin (LMWH) have been used to examine the binding between several preparations of LMWH and heparin-binding foldamers, which have recently been developed as potential inhibitors of the anticoagulant activity of LMWHs. It was found that the structure of the heparin-binding foldamer affects the equilibrium binding constant, K(eq), determined by analysis of the titration curves of the foldamers with LMWHs monitored with these electrodes, and further, the strength of binding depends on the specific LMWH preparation. Additionally, polymer membrane-based electrodes utilizing dinonylnaphthalene sulfonate as the ion-exchanger were developed to measure the heparin-binding foldamers directly in whole blood, and the response was found to depend on the lipophilicity and charge density of the foldamer.     

Enhanced sensitivity electrochemical assay of low-molecular-weight heparins using rotating polyion-sensitive membrane electrodes

Use of a novel rotating polycation-sensitive polymer membrane electrode yields sensors that can serve as simple potentiometric titration endpoint detectors for the determination of three FDA approved low-molecular-weight heparin (LMWH) anticoagulant drugs (Fragmin, Normiflo, and Lovenox). The rotating electrode configuration dramatically improves the reproducibility and increases the sensitivity for LMWH determinations by protamine titration. At a rotation speed of 3000 rpm, electrodes with optimized thin (50 µm) polymer membranes doped with dinonylnaphthalene sulfonate (DNNS) respond to low levels of protamine (<2 µg mL^–1) with good precision (±1 mV, N=10), when protamine is infused continuously into a Tris-buffer solution, pH 7.4. When infusing protamine (at 5 µg min^–1) continuously into solutions containing Fragmin, a clear endpoint is obtained, with the amount of protamine required to reach this endpoint proportional to the level of Fragmin present. A detection limit of less than 0.02 U mL^–1 Fragmin can be obtained via this new method, approximately one order of magnitude lower than that previously reported based on a non-rotating polycation electrode. Similar low detection limits can be achieved for potentiometric titrations of Normiflo and Lovenox. Such titrations can also be carried out in undiluted plasma samples containing the various LMWH species. In this case, detection of the LMWHs at clinically relevant concentrations (>0.2 U mL^–1) can be readily achieved.     

Polycationic calix[8]arenes able to recognize and neutralize heparin

A mutual induced fit mechanism is responsible for the exceptional complexation performances exhibited by calix[8]arene polycations towards heparin. The recognition process was studied in comparison with two other heparin antagonists: protamine and polylysine. The arrangement of multiple functional groups on the flexible macrocyclic scaffold of calix[8]arene, with respect to the conformationally rigid protamine and low ordered polylysine, allowed a mutual adaptability between calixarene polycations and heparin, significantly enhancing the recognition performances. Fluorescence, NMR titration, and activated partial thromboplastin time (aPTT) experiments confirmed that these calixarene derivatives have a very high specificity and affinity towards heparin neutralization as in aqueous solution as in blood. Analogous results were obtained with low molecular weight heparin (LMWH) whose effect protamine is unable to completely reverse.     

Structural elucidation of the tetrasaccharide pool in enoxaparin sodium

Low-molecular-weight heparins (LMWHs) are produced from heparin by various depolymerization strategies, which result in a reduction of the average molecular weight of the polysaccharide chains, a reduction of the anti-factor IIa activity (and a concomitant increase in the anti-factor Xa/anti-factor IIa ratio), and introduction of process-related structural signatures. Numerous techniques have been developed to characterize LMWHs and to measure the type and extent of structural modifications that are introduced as a function of the depolymerization process. We present here an analysis of the tetrasaccharide pool of enoxaparin sodium, a LMWH produced by chemical β-elimination of heparin benzyl ester. We identify the predominant sequences present within the tetrasaccharide pool and demonstrate that this pool provides a sensitive, specific readout of the physicochemical process conditions used to generate enoxaparin sodium.     

The electrochemistry of some drug interactions

Conductometric and spectrophotometric techniques were used to investigate possible interactions between heparin and lignocaine, heparin and chlorpromazine and chlorpromazine and lignocaine. The same techniques were applied to the well known interaction between heparin and protamine sulphate. Possible mechanisms for the interactions involved are discussed and the physico-chemical observations correlated with clinical studies in the case of lignocaine and heparin. Chlorpromazine and lignocaine yielded conductivity maxima indicating a charge transfer complex interaction at a mainly 4:1 chlorpromazine to lignocaine stoichiometry. The electron affinity of lignocaine was estimated at approximately 1.0 eV. No interaction was detected between lignocaine and heparin. Chlorpromazine and heparin showed evidence of an interaction as indicated by a conductivity minimum at a 1:1 stoichiometry. Protamine and heparin exhibited, as expected, an interaction which featured only a minor contribution from interactions involving free charge carriers.     

Recent advances in mass spectrometry analysis of low molecular weight heparins

Low molecular weight heparins (LMWHs) are the most widely used anticoagulant drugs produced by chemical or enzymatic modification of parent heparin polysaccharides. The present article reviews recent advances in orthogonal and complementary mass spectrometry (MS) methodologies towards complete elucidation of natural and modified structures in LMWHs that possibly affect the drug quality, safety and efficacy.     

Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management

Heparin, a linear glycosaminoglycan, is used in different forms in anticoagulation treatment. Protamine, a highly positive charged peptide containing about 32 amino acids, acts as an antagonist for heparin to restore normal blood coagulation. The complex formation of protamine with heparin was analyzed by a combination of analytical ultracentrifugation and light scattering. Titration of heparin with protamine in blood plasma preparations results in a drastic increase of turbidity, indicating the formation of nanoscale particles. A similar increase of turbidity was observed in physiological saline solution with or without human serum albumin (HSA). Particle size analysis by analytical ultracentrifugation revealed a particle radius of approximately 30 nm for unfractionated heparin and of approximately 60 nm for low molecular weight heparin upon complexation with excess protamine, in agreement with atomic force microscopy data. In the absence of HSA, larger and more heterogeneous particles were observed. The particles obtained were found to be stable for hours. The particle formation kinetics was analyzed by light scattering at different scattering angles and was found to be complete within several minutes. The time course of particle formation suggests a condensation reaction, with sigmoidal traces for low heparin concentrations and quasi-first-order reaction for high heparin concentrations. Under all conditions, the final scattering intensity reached after several minutes was found to be proportional to the amount of heparin in the blood plasma or buffer solution, provided that excess protamine was available and no multiple scattering occurred. On the basis of a direct relation between particle concentration and the heparin concentration present before protaminization, a light scattering assay was developed which permits the quantitative analysis of the heparin concentration in blood plasma and which could complement or even replace the activated clotting time test, which is currently the most commonly used method for blood coagulation management.     

体积排阻色谱法测定低分子量肝素抗凝血因子Xa的活性

发展了一种基于体积排阻色谱测定低分子量肝素(LMWH)抗凝血活性的方法。利用肝素与抗凝血酶Ⅲ(ATⅢ)结合后可增强ATⅢ对凝血因子Xa(FXa)抑制作用的原理,通过测定加入LMWH后FXa水解其生色底物产生对硝基苯胺(pNA)这一反应的抑制程度确定LMWH的活性。首先将含有一定浓度LMWH的缓冲溶液与ATⅢ溶液混合,然后依次加入FXa和生色底物,分别孵育一段时间。底物被FXa水解,产生游离的pNA。体积排阻色谱可将小分子产物pNA与其他大分子分离开,因而可以在pNA的最大吸收波长下得到高灵敏度的测定,并且不再受其他成分的干扰。该方法重复性好,灵敏度高,极大地减少了样品的消耗量,降低了成本,并且还可进行各种复杂样品(如血浆)中LMWH抗FXa活性的监测。     

毛细管电泳法测定肝素和低分子量肝素平均硫酸化程度

肝素和低分子量肝素（LMWHs）作为临床上常用的抗凝血药物,其抗凝血活性与硫酸化程度（SD）密切相关。然而,肝素类药物的生产需经历一系列复杂的工艺过程,在制备和储存过程中,肝素的硫酸基团容易水解丢失,影响抗凝血活性,这将直接影响肝素药物的使用安全性。为保证产品质量,需要发展一种快速检测肝素硫酸化程度的技术,以监测原料质量和工艺条件的稳定性。虽然已有一些测定肝素硫酸化程度的报道,但这些方法均有局限性,不适用于肝素生产的质量控制。为此,开发了一种基于毛细管电泳技术（CE）检测肝素和低分子量肝素的平均硫酸化程度的方法。首先,用肝素酶混合液彻底消化未分级肝素（UHF）和低分子量肝素,然后用毛细管电泳分离酶解得到的所有寡糖和二糖构建模块,并对它们进行定性和定量分析。随后,根据每种寡糖和二糖的峰面积及其硫酸酯基团的数量,便可计算出每个构成肝素二糖单元硫酸化程度的平均值。使用该方法对来自两个生产商各4个批次依诺肝素（低分子量肝素）和5个批次肝素原料进行检测,并计算了各批次样品的相对标准偏差（RSD）,对不同厂家生产的依诺肝素平均硫酸化程度进行了比较,验证了该方法的实用性。该方法灵敏度高,准确可靠,分析速度快,在肝素类药物生产过程的质量控制中具有良好的应用潜力。     

Linear polyalkylamines as fingerprinting agents in capillary electrophoresis of low-molecular-weight heparins and glycosaminoglycans

Glycosaminoglycan (GAG) analysis represents a challenging frontier despite the advent of many high‐resolution technologies because of their unparalleled structural complexity. We previously developed a resolving agent‐aided capillary electrophoretic approach for fingerprinting low‐molecular‐weight heparins (LMWHs) to profile their microscopic differences and assess batch‐to‐batch variability. In this report, we study the application of this approach for fingerprinting other GAGs and analyze the basis for the fingerprints observed in CE. Although the resolving agents, linear polyalkylamines, could resolve the broad featureless electropherogram of LMWH into a large number of distinct, highly reproducible peaks, longer GAGs such as chondroitin sulfate, dermatan sulfate, and heparin responded in a highly individualistic manner. Full‐length heparin interacted with linear polyalkylamines very strongly followed by dermatan sulfate, whereas chondroitin sulfate remained essentially unaffected. Oversulfated chondroitin sulfate could be easily identified from full‐length heparin. Scatchard analysis of the binding profile of enoxaparin with three linear polyalkylamines displayed a biphasic binding profile suggesting two distinctly different types of interactions. Some LMWH chains were found to interact with linear polyalkylamines with affinities as high as 10 nM, whereas others displayed nearly 5000‐fold weaker affinities. These observations provide fundamental insight into the basis for fingerprinting of LMWHs by linear polyalkylamine‐based resolving agents, which could be utilized in the design of advanced resolving agents for compositional profiling, direct sequencing, and chemoinformatics studies.     

Low molecular weight heparin enhances prostacyclin production by cultured human endothelial cells.

Confluent cultures of vascular endothelial cells derived from the human umbilical vein were incubated in a serum-free medium in the presence of low molecular weight heparin (LMWH) with molecular weights of 4000-6000 dalton (Da), or of unfractionated heparin (UFH) with average molecular weight 12,000 Da, and prostacyclin production was determined by radioimmunoassay for 6-keto-prostaglandin F1 alpha, the stable metabolite of prostacyclin. LMWH at 1 U/ml as anti-factor Xa activity significantly increased prostacyclin production after 6h or longer; however, UFH at 1 USP U/ml did not induce such a significant change. The LMWH-induced increase in prostacyclin production occurred at 0.1 U/ml and above after 6 h of treatment. Since prostacyclin is both a potent inhibitor of platelet aggregation and a vasodilator, it was suggested that the increased endothelial cell prostacyclin production induced by LMWH may be a component of the anticoagulant activity of the drug.     

Surface Modification of Polyurethanes with Covalent Immobilization of Heparin

Thrombus formation and blood coagulation is a major problem associated with blood contacting products such as catheters, vascular grafts, arteries, artificial hearts and heart valves. An intense research is being conducted towards the synthesis of new hemocompatible materials and modifications of surfaces with biological molecules. In this study, polyurethane (PU) films were synthesized in medical purity from diisocyanate and polyol without using any other ingredients and their surfaces were modified by covalent immobilization of heparin. Two types of heparin, unfractionated (UFH) and low molecular weight heparin (LMWH), were immobilized to investigate their effect on cell adhesion. The surface properties of the modified PUs were examined with ESCA, ATR-FTIR and AFM. ESCA results demonstrated sulfur peaks indicating the presence of heparin and AFM results showed the alteration of surface structure after coating with heparin. Cell adhesion studies were conducted with heparinized whole human blood. The surfaces of the UFH immobilized films resulted in lesser red blood cell adhesion in comparison to LMWH demonstrating strong anti-thrombogenic activity of the latter.     

Qualitative analysis of enzymatic and chemical depolymerized low molecular weight heparins by UHPLC coupled with electrospray ionization quadrupole time‐of‐flight‐mass spectrometry

Complete heparin digestion with heparin lyase I and II results in a mixture of hexasaccharides and tetrasaccharides with 3‐O‐sulfo group‐containing glucosamine residues at their reducing ends. Because these tetrasaccharides are derived from antithrombin III‐binding sites of heparin, we examined whether this method could be applied to estimate the anticoagulant activity of heparin. Therefore, this paper presents a new low molecular weight heparin sample preparation method–chemical depolymerization. Qualitative analysis of the studied compounds and a comparison of their composition are an important contribution to the structural analysis of low molecular weight heparins, which has not been fully conducted so far. Qualitative on‐line liquid chromatography–mass spectrometric analysis of these resistant oligosaccharides is also described in this paper.     

Characterization of currently marketed heparin products: analysis of molecular weight and heparinase-I digest patterns

We evaluated polyacrylamide gel electrophoresis (PAGE) and size exclusion chromatography coupled with multi-angle laser light scattering (SEC-MALLS) approaches to determine weight-average molecular weight (M _w) and polydispersity (PD) of heparins. A set of unfractionated heparin sodium (UFH) and low-molecular-weight heparin (LMWH) samples obtained from nine manufacturers which supply the US market were assessed. For SEC-MALLS, we measured values for water content, refractive index increment (dn/dc), and the second virial coefficient (A ₂) for each sample prior to molecular weight assessment. For UFH, a mean ± standard deviation value for M _w of 16,773 ± 797 was observed with a range of 15,620 to 18,363 (n = 20, run in triplicate). For LMWHs by SEC-MALLS, we measured mean M _w values for dalteparin, tinzaparin, and enoxaparin of 6,717 ± 71 (n = 4), 6,670 ± 417 (n = 3), and 3,959 ± 145 (n = 3), respectively. PAGE analysis of the same UFH, dalteparin, tinzaparin, and enoxaparin samples showed values of 16,135 ± 643 (n = 20), 5,845 ± 45 (n = 4), 6,049 ± 95 (n = 3), and 4,772 ± 69 (n = 3), respectively. These orthogonal measurements are the first M _w results obtained with a large heparin sample set on product being marketed after the heparin crisis of 2008 changed the level of scrutiny of this drug class. In this study, we compare our new data set to samples analyzed over 10 years earlier. In addition, we found that the PAGE analysis of heparinase digested UFH and neat LMWH samples yield characteristic patterns that provide a facile approach for identification and assessment of drug quality and uniformity.     

Protamine/heparin optical nanosensors based on solvatochromism

Optical nanosensors for the detection of polyions, including protamine and heparin, have to date relied upon ion-exchange reactions involving an analyte and an optical transducer. Unfortunately, due to the limited selectivity of the available ionophores for polyions, this mechanism has suffered from severe interference in complex sample matrices. To date no optical polyion nanosensors have demonstrated acceptable performance in serum, plasma or blood. Herein we describe a new type of nanosensor based on our discovery of a “hyper-polarizing lipophilic phase” in which dinonylnaphthalenesulfonate (DNNS⁻) polarizes a solvatochromic dye much more than even an aqueous environment. We have found that the apparent polarity of the organic phase is only modulated when DNNS⁻ binds to large polyions such as protamine, unlike singly charged ions that lack the cooperative binding required to cause a significant shift in the distribution of the polarizing DNNS⁻ ions. Our new sensing mechanism allows solvatochromic signal transduction without the transducer undergoing ion exchange. The result is significantly improved sensitivity and selectivity, enabling for the first time the quantification of protamine and heparin in human plasma using optical nanosensors that correlates with the current gold standard analysis method, the anti-Xa factor assay.

Novel optical nanosensors for the selective detection of the polycationic protamine based on solvatochromic signal change allow one to detect heparin in plasma.     

胶束电动色谱柱上酶反应测定低分子量肝素的抗凝血活性

发展了一种基于胶束电动色谱（MEKC）结合柱上酶微反应的方法,用于测定低分子量肝素（LMWHs）的抗凝血活性。肝素与抗凝血酶Ⅲ（ATⅢ）结合后,将ATⅢ抑制凝血因子10（FXa）活性提高了约1000倍。通过测定FXa水解生色肽底物CPS产生的对硝基苯胺（p -NP）就可以测定FXa的活性。因此,通过LMWHs抑制FXa产生的对硝基苯胺的量就可以测定抗凝血活性。该方法将毛细管柱端作为微量的酶微反应器,以呋喃妥英（nitrofurantoin,NF）作为内标,依次将LMWHs溶液、ATⅢ溶液、FXa和CPS溶液导入毛细管柱端,反应物经过分子扩散、横向层流扩散混合和电压混合后反应。反应结束后,采用MEKC分离模式将产物对硝基苯胺与底物以及其他大分子分离,在其最大波长380 nm下测定产生对硝基苯胺的量,从而确定LMWHs的抗凝血活性。该方法具有自动化、重复性好、灵敏度高、样品消耗量少的优点,而且不受其他成分的干扰,可用于各种复杂样品（如血浆）中LMWHs抗FXa活性的监测。     

Structural characterization of heparins from different commercial sources

Seven commercial heparin active pharmaceutical ingredients and one commercial low molecular weight from different manufacturers were characterized with a view profiling their physicochemical properties. All heparins had similar molecular weight properties as determined by polyacrylamide gel electrophoresis (M _N, 10–11 kDa; M _W, 13–14 kDa; polydispersity (PD), 1.3–1.4) and by size exclusion chromatography (M _N, 14–16 kDa; M _W, 21–25 kDa; PD, 1.4–1.6). one-dimensional ¹H- and ¹³C-nuclear magnetic resonance (NMR) evaluation of the heparin samples was performed, and peaks were fully assigned using two-dimensional NMR. The percentage of glucosamine residues with 3-O-sulfo groups and the percentage of N-sulfo groups and N-acetyl groups ranged from 5.8–7.9%, 78–82%, to 13–14%, respectively. There was substantial variability observed in the disaccharide composition, as determined by high performance liquid chromatography (HPLC)-mass spectral analysis of heparin lyase I–III digested heparins. Heparin oligosaccharide mapping was performed using HPLC following separate treatments with heparin lyase I, II, and III. These maps were useful in qualitatively and quantitatively identifying structural differences between these heparins. The binding affinities of these heparins to antithrombin III and thrombin were evaluated by using a surface plasmon resonance competitive binding assay. This study provides the physicochemical and activity characterization necessary for the appropriate design and synthesis of a generic bioengineered heparin.     

Injectable Nanohybrid Scaffold for Biopharmaceuticals Delivery and Soft Tissue Engineering

An injectable nanofibrous hydrogel scaffold integrated with growth factors (GFs) loaded polysaccharide nanoparticles was developed that specifically allows for targeted adipose‐derived stem cells (ASCs) encapsulation and soft tissue engineering. The nanofibrous hydrogel was produced via biological conjugation of biotin‐terminated star‐shaped poly(ethylene glycol) (PEG‐Biotin) and streptavidin‐functionalized hyaluronic acid (HA‐Streptavidin). The polysaccharide nanoparticles were noncovalently assembled via electrostatic interactions between low‐molecular‐weight heparin (LMWH) and N,N,N‐trimethylchitosan chloride (TMC). Vascular endothelial growth factor (VEGF) was entrapped in the LMWH/TMC nanoparticles by affinity interactions with LMWH.     

High-performance liquid chromatographic analysis of g;ycosaminoglycan-derived oligosaccharides

High-performance liquid chromatography of glycosaminoglycan (GAG)-derived oligosaccharides has been employed for structural analysis and measurement of hyaluronan, chondroitin sulphate, dermatan sulphate, keratan sulphate, herapan sulphate and heparin. Recent developments in the separation and detection of unsaturated dissacharides and oligosaccharides derived from GAGs by enzyme or chemical degradation are reviewed.     

Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments

Periodate oxidation followed by borohydride reduction converts the well-known antithrombotics heparin and low-molecular-weight heparins (LMWHs) into their “glycol-split” (gs) derivatives of the “reduced oxyheparin” (RO) type, some of which are currently being developed as potential anti-cancer and anti-inflammatory drugs. Whereas the structure of gs-heparins has been recently studied, details of the more complex and more bioavailable gs-LMWHs have not been yet reported. We obtained RO derivatives of the three most common LMWHs (tinzaparin, enoxaparin, and dalteparin) and studied their structures by two-dimensional nuclear magnetic resonance spectroscopy and ion-pair reversed-phase high-performance liquid chromatography coupled with electrospray ionization mass spectrometry. The liquid chromatography–mass spectrometry (LC-MS) analysis was extended to their heparinase-generated oligosaccharides. The combined NMR/LC-MS analysis of RO-LMWHs provided evidence for glycol-splitting-induced transformations mainly involving internal nonsulfated glucuronic and iduronic acid residues (including partial hydrolysis with formation of “remnants”) and for the hydrolysis of the gs uronic acid residues when formed at the non-reducing ends (mainly, in RO-dalteparin). Evidence for minor modifications, such as ring contraction of some dalteparin internal aminosugar residues, was also obtained. Unexpectedly, the N-sulfated 1,6-anhydromannosamine residues at the enoxaparin reducing end were found to be susceptible to the periodate oxidation. In addition, in tinzaparin and enoxaparin, the borohydride reduction converts the hemiacetalic aminosugars at the reducing end to alditols. Typical LC-MS signatures of RO-derivatives of individual LMWH both before and after digestion with heparinases included oligosaccharides generated from the original antithrombin-binding and “linkage” regions.